Who are dl-3-n-butylphthalide (NBP)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Remodulin, Flolan, Monoket, Rogaine, Nitroglycerin, NITROGLYCERIN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dl-3-n-butylphthalide-nbp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

dl-3-n-butylphthalide (NBP) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dl-3-n-butylphthalide (NBP) (dl-3-n-butylphthalide (NBP)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vasodilator. Area: Cerebrovascular Disease.

phase 3 vasodilator Cerebrovascular Disease Small molecule Live · refreshed every 30 min

Target snapshot

dl-3-n-butylphthalide (NBP) (dl-3-n-butylphthalide (NBP)) — yuanli Zhao. DL-3-n-butylphthalide (NBP) is a small molecule that acts as a vasodilator and neuroprotective agent.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dl-3-n-butylphthalide (NBP) TARGET	dl-3-n-butylphthalide (NBP)	yuanli Zhao	phase 3	vasodilator
Remodulin	TREPROSTINIL	United Therap	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	2002-01-01
Flolan	EPOPROSTENOL	AstraZeneca	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	1995-01-01
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
Rogaine	minoxidil	Generic (originally Upjohn/Pfizer)	marketed	Vasodilator (potassium channel opener), Hair growth stimulant	ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2	1988-08-18
Nitroglycerin	glyceryl trinitrate	Fougera	marketed	Nitrate Vasodilator [EPC]	guanylate cyclase	1981-01-01
NITROGLYCERIN	NITROGLYCERIN		marketed	Nitrate Vasodilator [EPC]	Nitric oxide synthase pathway	1981-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-03-12 — Nitroglycerin · 7872049 · US
2029-03-12 — NITROGLYCERIN · 7872049 · Formulation · US
2032-03-11 — Nitroglycerin · 9101592 · US
2032-03-11 — NITROGLYCERIN · 9101592 · Formulation · US

Sponsor landscape (vasodilator class)

Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 drug in this class
Hvidovre University Hospital · 1 drug in this class
United States Naval Medical Center, San Diego · 1 drug in this class
yuanli Zhao · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dl-3-n-butylphthalide (NBP) — Competitive Intelligence Brief. https://druglandscape.com/ci/dl-3-n-butylphthalide-nbp. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab